Biotech stocks jump on AbbVie deal to buy cancer drugmaker ImmunoGen for $10 billion

Shares of other biotech companies developing ADCs, which are among the hottest areas in the pharmaceutical industry, jumped on the news of the buyout.

Previous post Nashville added nearly 100 new residents per day in 2022. Here’s why people are moving to Music City
Next post : Meta challenges FTC’s ‘constitutional authority’ in lawsuit about consent agreement